- Home
- BCDA vs SBFM Comparison
BCDA vs SBFM Comparison
Compare BCDA & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- SBFM
- Stock Information
- Founded
- BCDA N/A
- SBFM 2006
- Country
- BCDA United States
- SBFM United States
- Employees
- BCDA 17
- SBFM N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- SBFM Health Care
- Exchange
- BCDA Nasdaq
- SBFM Nasdaq
- Market Cap
- BCDA 10.1M
- SBFM 6.6M
- IPO Year
- BCDA N/A
- SBFM N/A
- Fundamental
- Price
- BCDA $2.10
- SBFM $1.47
- Analyst Decision
- BCDA Strong Buy
- SBFM Strong Buy
- Analyst Count
- BCDA 1
- SBFM 1
- Target Price
- BCDA $25.00
- SBFM $15.00
- AVG Volume (30 Days)
- BCDA 208.8K
- SBFM 183.9K
- Earning Date
- BCDA 08-12-2025
- SBFM 08-15-2025
- Dividend Yield
- BCDA N/A
- SBFM N/A
- EPS Growth
- BCDA N/A
- SBFM N/A
- EPS
- BCDA N/A
- SBFM N/A
- Revenue
- BCDA $3,000.00
- SBFM $36,234,578.00
- Revenue This Year
- BCDA N/A
- SBFM $192.48
- Revenue Next Year
- BCDA N/A
- SBFM N/A
- P/E Ratio
- BCDA N/A
- SBFM N/A
- Revenue Growth
- BCDA N/A
- SBFM 35.51
- 52 Week Low
- BCDA $1.63
- SBFM $1.17
- 52 Week High
- BCDA $4.66
- SBFM $7.60
- Technical
- Relative Strength Index (RSI)
- BCDA 47.19
- SBFM 48.32
- Support Level
- BCDA $1.98
- SBFM $1.42
- Resistance Level
- BCDA $2.19
- SBFM $1.75
- Average True Range (ATR)
- BCDA 0.16
- SBFM 0.13
- MACD
- BCDA -0.00
- SBFM 0.00
- Stochastic Oscillator
- BCDA 30.00
- SBFM 22.22
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.